Welcome to our dedicated page for Ionis Pharmaceuticals SEC filings (Ticker: IONS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ionis Pharmaceuticals, Inc. filings document an operating biotechnology company focused on RNA-targeted medicines, marketed products, partnered programs, and clinical-stage pipeline assets. Form 8-K reports cover GAAP and non-GAAP financial results, product-sales updates, Regulation FD disclosures, clinical data releases, and regulatory communications involving programs such as zilganersen in Alexander disease and bepirovirsen in chronic hepatitis B.
Proxy materials describe annual meeting procedures, director matters, board governance, and stockholder voting items. Other filings record capital-structure events and material agreements, including the completed private offering of convertible senior notes due 2030, along with exhibit filings and related corporate disclosures.
Patrick R. O'Neil, Executive Vice President, Chief Legal Officer & General Counsel of Ionis Pharmaceuticals (IONS), reported option exercises and subsequent sales on September 29-30, 2025. The Form 4 shows Mr. O'Neil acquired 10,473 shares on 09/29/2025 and 14,827 shares on 09/30/2025 via exercise of non-qualified stock options with an exercise price of $56.78 per share. On the same dates he sold the exercised shares: 10,473 shares on 09/29/2025 at a weighted average price of $64.5417, and 14,827 shares on 09/30/2025 at a weighted average price of $64.6777. The sales were executed pursuant to a Rule 10b5-1 trading plan adopted May 2, 2025. Following these transactions, Mr. O'Neil beneficially owned 57,130 shares.
Richard S. Geary, EVP & Chief Development Officer of Ionis Pharmaceuticals (IONS), reported option exercise and share sales on 09/30/2025. He exercised a non-qualified stock option with a $53.77 exercise price to acquire 57,900 shares, increasing his direct beneficial ownership to 137,557 shares. On the same date he sold 57,900 shares under a Rule 10b5-1 trading plan adopted May 6, 2025, for a weighted-average price of $65.2447 per share, with individual sale prices in the $65.00 to $65.52 range. The filing was submitted by an attorney-in-fact.
IONIS PHARMACEUTICALS, INC. (IONS) submitted a Form 144 reporting a proposed sale of 27,114 shares of common stock through Stifel Nicolaus & Company on Nasdaq, with an aggregate market value of $1,789,524 and total shares outstanding reported as 159,391,229. The filer reports acquiring 17,114 of these shares on 01/15/2021 by option exercise, with payment listed as cash and an approximate sale date of 10/01/2025.
The filing also discloses a prior sale by the same person on 09/02/2025 of 11,130 shares for $552,865. By simple proportion, the proposed sale represents approximately 0.017% of outstanding shares, indicating the transaction is small relative to the company's share count. The notice contains the standard insider representation about absence of undisclosed material information.
Form 144 filing by Ionis Pharmaceuticals (IONS) reports a proposed sale of 49,800 shares of common stock through Stifel Nicolaus & Company, with an aggregate market value of $3,249,734.00. The shares are listed on Nasdaq and the filing lists 159,391,229 shares outstanding for the issuer. The securities were acquired on 01/02/2019 by option exercise from the issuer and the intended sale is scheduled for 09/30/2025 with payment in cash. The filer reports no sales in the past three months and includes the standard representation that the seller does not possess undisclosed material adverse information.
Ionis Pharmaceuticals announced positive topline results from the pivotal study of zilganersen 50 mg in children and adults with Alexander disease (AxD). The drug met the study's primary endpoint: stabilization in gait speed on the 10-Meter Walk Test at week 61, showing a mean difference of 33.3% (p=0.0412) versus control. The company reports consistent benefit across key secondary endpoints related to patient- and clinician-reported measures and says safety and tolerability were favorable, with most adverse events mild or moderate and serious adverse events numerically lower in the zilganersen arm.
Ionis plans to submit a new drug application to the U.S. FDA in Q1 2026 and is evaluating an Expanded Access Program in the U.S. Detailed data will be presented at an upcoming medical conference.
Ionis Pharmaceuticals announced positive topline results from the pivotal study of zilganersen 50 mg in children and adults with Alexander disease (AxD). The drug met the study's primary endpoint: stabilization in gait speed on the 10-Meter Walk Test at week 61, showing a mean difference of 33.3% (p=0.0412) versus control. The company reports consistent benefit across key secondary endpoints related to patient- and clinician-reported measures and says safety and tolerability were favorable, with most adverse events mild or moderate and serious adverse events numerically lower in the zilganersen arm.
Ionis plans to submit a new drug application to the U.S. FDA in Q1 2026 and is evaluating an Expanded Access Program in the U.S. Detailed data will be presented at an upcoming medical conference.
Patrick R. O'Neil, Executive Vice President, Chief Legal Officer and General Counsel of Ionis Pharmaceuticals (IONS), reported option exercise and an offsetting sale on 09/12/2025. He exercised a non-qualified stock option to purchase 1,700 shares at a $56.78 exercise price and concurrently sold 1,700 shares under a Rule 10b5-1 trading plan for a weighted average price of $64.5807, leaving him with 55,503 shares directly owned and 57,130 shares following the transactions as reported. The filing includes an explanation that the shares sold were transacted at prices ranging from $64.53 to $64.605 and that the sale was pursuant to a 10b5-1 plan adopted May 2, 2025.
Insider transactions by Joseph T. Baroldi at Ionis Pharmaceuticals (IONS) On 09/09/2025 Mr. Baroldi executed related transactions reported on Form 4. He exercised a non-qualified stock option with a $31.80 exercise price to acquire 11,950 shares and, pursuant to a Rule 10b5-1 trading plan adopted May 2, 2025, sold 11,950 shares at a weighted-average price of $62.1622 (individual sale prices ranged $62.00–$62.44). The Form 4 shows beneficial ownership figures of 43,876 shares (after the acquisition line) and 31,926 shares (after the sale line), and additionally notes 3,071 shares indirectly owned by his spouse. The filing was signed by an attorney-in-fact on 09/10/2025.
Insider transactions by Patrick R. O'Neil, EVP, CLO & General Counsel of Ionis Pharmaceuticals (IONS): The Form 4 reports multiple transactions dated 09/09/2025 showing both acquisitions and dispositions of Ionis common stock and related options. The reporting person acquired 21,000 shares (20,000 and 1,000) via option-related transactions at exercise prices shown and sold 21,000 shares under a Rule 10b5-1 trading plan at a weighted average sale price of $64.5553 per share. Following the reported activity the filer beneficially owns between 57,130 and 77,203 shares depending on the line item.
The filing discloses that the sales were made pursuant to a 10b5-1 plan adopted May 2, 2025, and that the reported sale price is a weighted average reflecting multiple executions between $64.50 and $64.66. The filer offers to provide detailed per-trade prices on request.
Joseph T. Baroldi, EVP and Chief Business Officer of Ionis Pharmaceuticals (IONS), reported multiple Section 16 transactions on 09/05/2025 under a previously adopted Rule 10b5-1 plan. He exercised 250 non-qualified stock options with a $31.80 exercise price and immediately acquired 250 shares. Simultaneously, he sold 250 shares pursuant to his 10b5-1 plan at an average price of $62, leaving him with 32,176 shares directly and 3,071 shares indirectly held by his spouse. After the option exercise, total direct beneficial ownership of common stock reported is 53,650 shares.
The filing discloses the trades were executed pursuant to a 10b5-1 trading plan adopted May 2, 2025, and the Form 4 was signed by an attorney-in-fact on 09/09/2025. No other compensatory or material corporate events are disclosed in this Form 4.
Insider sale recorded on Form 4: Ionis Pharmaceuticals EVP and Chief Scientific Officer C. Frank Bennett sold 6,000 shares of Ionis common stock on 09/05/2025 at a weighted average price of $59.5968 per share, reducing his beneficial ownership to 82,679 shares. The sales were made pursuant to a Rule 10b5-1 trading plan adopted May 13, 2025, and occurred in multiple transactions at prices ranging from $59.25 to $59.86. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Bennett on 09/09/2025.